ArticleOncogene2016
Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation.
Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Association among Noncoding-RNAs, APRO Family Proteins, and Gut Microbiota in the Development of Breast Cancer.Oncology research · 2025Review
- Transcription factor E4F1 as a regulator of cell life and disease progression.Science advances · 2023Review
- Article
- The Overexpression of TOB1 Induces Autophagy in Gastric Cancer Cells by Secreting Exosomes.Disease markers · 2022Article
- HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.Cancer letters · 2021Article
- A genome-wide atlas of co-essential modules assigns function to uncharacterized genes.Nature genetics · 2021Article
- Functional genetic diversity of domestic and wild American mink (Evolutionary applications · 2020Article
- TOB1 suppresses proliferation in K-Ras wild-type pancreatic cancer.Cancer medicine · 2020Article
- RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack.Methods in enzymology · 2020Article
- Identification and Development of Long Non-coding RNA Associated Regulatory Network in Pancreatic Adenocarcinoma.OncoTargets and therapy · 2020Article
- TOB1-AS1 suppresses non-small cell lung cancer cell migration and invasion through a ceRNA network.Experimental and therapeutic medicine · 2019Article
- Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.Molecular systems biology · 2019Article
- High expression of Tob1 indicates poor survival outcome and promotes tumour progression via a Wnt positive feedback loop in colon cancer.Molecular cancer · 2018Article
- Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.JNCI cancer spectrum · 2018Article
- Association between the SNPs of theJournal of Cancer · 2018Article
- Protein network construction using reverse phase protein array data.Methods (San Diego, Calif.) · 2017Article
- Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.Oncotarget · 2017Article
- RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells.Bio-protocol · 2017Article
- Transducer of ERBB2.1 (TOB1) as a Tumor Suppressor: A Mechanistic Perspective.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
Resistance to therapies targeting the estrogen pathway remains a challenge in the treatment of estrogen receptor-positive breast cancer. To address this challenge, a systems biology approach was used. A library of small interfering RNAs targeting an estrogen receptor (ER)- and aromatase-centered network identified 46 genes that are dispensable in estrogen-dependent MCF7 cells, but are selectively required for the survival of estrogen-independent MCF7-derived cells and multiple additional estrogen-independent breast cancer cell lines. Integration of this information identified a tumor suppressor gene TOB1 as a critical determinant of estrogen-independent ER-positive breast cell survival. Depletion of TOB1 selectively promoted G1 phase arrest and sensitivity to AKT and mammalian target of rapmycin (mTOR) inhibitors in estrogen-independent cells but not in estrogen-dependent cells. Phosphoproteomic profiles from reverse-phase protein array analysis supported by mRNA profiling identified a significant signaling network reprogramming by TOB1 that differed in estrogen-sensitive and estrogen-resistant cell lines. These data support a novel function for TOB1 in mediating survival of estrogen-independent breast cancers. These studies also provide evidence for combining TOB1 inhibition and AKT/mTOR inhibition as a therapeutic strategy, with potential translational significance for the management of patients with ER-positive breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.